Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab and Cemiplimab in EGFR- or LKB1-mutant NSCLC
NCT05704634Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2023
- Primary completion
- Jan 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sarilumab and cemiplimab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Dose-Limiting Toxicities, Objective Response Rate and 1 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
sarilumabcemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05704634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704634.